{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:33:47Z","timestamp":1794249227666,"version":"4.9.0"},"reference-count":43,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"11","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Glob Oncol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Sarcomatoid renal cell carcinoma (sRCC) represents a kidney malignancy with a sarcomatoid component associated with poor prognosis. Immunotherapy (IO)-based combinations demonstrated promising activity in sRCC, yet real-world evidence (RWE) remains limited. We aimed to characterize the clinicopathologic features and outcomes of patients with metastatic sRCC treated with first-line immune-based combinations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>This retrospective analysis from the ARON-1 study included 350 patients with histologically confirmed metastatic sRCC treated with first-line IO + IO, or IO + tyrosine kinase inhibitor across 66 centers in 21 countries (2016-2024). Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression methods. Correlations between 2-year OS and clinical variables were assessed using Pearson's coefficient.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      After a median follow-up of 19.1 months, median OS was 26.9 months (95% CI, 21.6 to 43.3). OS was longer in males (43.3\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      15.3 months in females;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), in whom underwent nephrectomy (32.3\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      20.7 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .002), and in patients without hepatic (32.3\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      15.3 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001), without skeletal (41.0\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      20.0 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .007), or without lymph node metastases (43.3\n                      <jats:italic toggle=\"yes\">v<\/jats:italic>\n                      24.6 months;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = .037). Median OS varied by International Metastatic RCC Database Consortium (IMDC) risk group: 66.5, 29.4, and 11.7 months in favorable-, intermediate-, and poor-risk patients, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). Different IO regimens showed variable outcomes by risk subgroup. Limitations include retrospective design and lack of central pathology review.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>First-line IO-based combinations provide clinically meaningful survival in sRCC, with outcomes affected by sex, metastatic sites, and IMDC risk. This RWE may support a tailored therapeutic approach on the basis of baseline prognostic factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/go-25-00376","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:59:33Z","timestamp":1761767973000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":8,"title":["Sarcomatoid Differentiation in Renal Cell Carcinoma: Clinical and Pathologic Heterogeneity and Outcomes With Immune Checkpoint Inhibitors\u2014Data From the ARON-1 Study"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-6871","authenticated-orcid":true,"given":"Francesco","family":"Massari","sequence":"first","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"},{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4920-9951","authenticated-orcid":true,"given":"Matteo","family":"Rosellini","sequence":"additional","affiliation":[{"name":"Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bohuslav","family":"Melichar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Faculty of Medicine and Dentistry, Palack\u00fd University, Olomouc, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0134-4732","authenticated-orcid":true,"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, MD Anderson Cancer Center Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3116-912X","authenticated-orcid":true,"given":"Maria T.","family":"Bourlon","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n, Mexico City, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-9378","authenticated-orcid":true,"given":"Haoran","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kansas Cancer Center, Kansas City, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-7385","authenticated-orcid":true,"given":"Ond\u0159ej","family":"Fiala","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic"},{"name":"Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-9326","authenticated-orcid":true,"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Sungkyunkwan University Samsung Medical Center, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7767-0200","authenticated-orcid":true,"given":"Maria Jos\u00e9 Juan","family":"Fita","sequence":"additional","affiliation":[{"name":"Medical Oncology, Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7936-5245","authenticated-orcid":true,"given":"Tarek","family":"Taha","sequence":"additional","affiliation":[{"name":"Royal Marsden NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-0598","authenticated-orcid":true,"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Radiological, Oncological and Pathological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1844-8474","authenticated-orcid":true,"given":"Alfonso G\u00f3mez","family":"de Lia\u00f1","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, CHU Insular-Materno Infantil, Las Palmas, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0316-9621","authenticated-orcid":true,"given":"Thomas","family":"B\u00fcttner","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Bonn, Bonn, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5814-2296","authenticated-orcid":true,"given":"Sarah","family":"Scagliarini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, AORN \u201cA. Cardarelli\u201d, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8106-9741","authenticated-orcid":true,"given":"Ray","family":"Manneh Kopp","sequence":"additional","affiliation":[{"name":"Clinical Oncology, Sociedad de Oncolog\u00eda y Hematolog\u00eda del Cesar, Valledupar, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2137-3140","authenticated-orcid":true,"given":"Annalisa","family":"Zeppellini","sequence":"additional","affiliation":[{"name":"Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1627-384X","authenticated-orcid":true,"given":"Marwan","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Hematology-Oncology Department, Faculty of Medicine, Saint Joseph University of Beirut, Beirut, Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenza","family":"Conteduca","sequence":"additional","affiliation":[{"name":"Unit of Medical Oncology and Biomolecular Therapy, Department of Medical and Surgical Sciences, University of Foggia, Policlinico Riuniti, Foggia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8659-7327","authenticated-orcid":true,"given":"Hatice","family":"B\u00f6lek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[{"name":"S.S.D. C.O.r.O. Bed Management Presa in Carico, TDM, IRCCS Istituto Tumori \u201cGiovanni Paolo II\u201d, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-548X","authenticated-orcid":true,"given":"Jawaher","family":"Ansari","sequence":"additional","affiliation":[{"name":"Medical Oncology, Tawam Hospital, Al Ain, UAE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[{"name":"Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zgura","sequence":"additional","affiliation":[{"name":"Department of Oncology-Radiotherapy, Prof. Dr. Alexandru Trestioreanu Institute of Oncology, \u201cCarol Davila\u201d University of Medicine and Pharmacy, Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Filosa","sequence":"additional","affiliation":[{"name":"Anatomic Pathology, Department of Biomedical Sciences and Public Health, University \u201cPolitecnica delle Marche\u201d, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2542-3714","authenticated-orcid":true,"given":"Ahmet","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1768-0503","authenticated-orcid":true,"given":"Umut","family":"Akova","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-8251","authenticated-orcid":true,"given":"Fernando Sabino Marques","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group\u2014LACOG, Porto Alegre, Brazil"},{"name":"Oncology and Hematology Department, Hospital S\u00edrio Liban\u00eas, Bras\u00edlia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-0226","authenticated-orcid":true,"given":"Sebastiano","family":"Buti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, University Hospital of Parma, Parma, Italy"},{"name":"Department of Medicine and Surgery, University of Parma, Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4980-6729","authenticated-orcid":true,"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[{"name":"Latin American Cooperative Oncology Group\u2014LACOG, Porto Alegre, Brazil"},{"name":"Oncology Unit, Hospital Israelita Albert Einstein, S\u00e3o Paulo, SP, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4003-1103","authenticated-orcid":true,"given":"Mehmet Asim","family":"Bilen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Emory University School of Medicine, Atlanta, GA"},{"name":"Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9152-9887","authenticated-orcid":true,"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[{"name":"Oncology Unit, Macerata Hospital, Macerata, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00382-9"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21288"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010099"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12781"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0227"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21068-9"},{"key":"e_1_3_7_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-024-00896-6"},{"key":"e_1_3_7_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0000"},{"key":"e_1_3_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00917-6"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005445"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4500"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.6_suppl.308"},{"key":"e_1_3_7_14_2","first-page":"1223282","article-title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms [published correction appears in Front Oncol. 2024 Mar 01;13:1343027. doi: 10.3389\/fonc.2023.1343027]","volume":"13","author":"Gr\u00fcnwald V","year":"2023","unstructured":"Gr\u00fcnwald V, Powles T, Eto M, et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms [published correction appears in Front Oncol. 2024 Mar 01;13:1343027. doi: 10.3389\/fonc.2023.1343027]. Front Oncol 13:1223282, 2023","journal-title":"Front Oncol"},{"key":"e_1_3_7_15_2","first-page":"145","article-title":"Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: Differential effectiveness by risk group?","volume":"23","author":"Santoni M","year":"2023","unstructured":"Santoni M, Buti S, Myint ZW, et al: Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database consortium criteria treated by immune-oncology combinations: Differential effectiveness by risk group? Eur Urol Oncol 23:145, 2023","journal-title":"Eur Urol Oncol"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-024-01096-3"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00978-2"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03719-0"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35141"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_7_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000002233"},{"key":"e_1_3_7_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0475"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.16609"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.10.019"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000001269"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-024-03876-2"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2024.03.014"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-71746-z"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00828-z"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-023-00540-9"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140257"},{"key":"e_1_3_7_33_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1233521"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-022-00676-0"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-97365-6"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10585-024-10327-w"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2025.155964"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.08.011"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.11.016"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.008"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.04.004"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2015.00202"},{"key":"e_1_3_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.10.011"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2128"}],"container-title":["JCO Global Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/GO-25-00376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:59:38Z","timestamp":1761767978000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/GO-25-00376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1200\/GO-25-00376"],"URL":"https:\/\/doi.org\/10.1200\/go-25-00376","relation":{},"ISSN":["2687-8941"],"issn-type":[{"value":"2687-8941","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2500376"}}